Strongbridge Biopharma plc (SBBP)’s Financial Results Comparing With Achaogen Inc. (NASDAQ:AKAO)

Strongbridge Biopharma plc (NASDAQ:SBBP) and Achaogen Inc. (NASDAQ:AKAO), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Strongbridge Biopharma plc 18.03M 15.98 31.85M -1.63 0.00
Achaogen Inc. 8.57M 4.15 175.37M -3.96 0.00

In table 1 we can see Strongbridge Biopharma plc and Achaogen Inc.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Strongbridge Biopharma plc and Achaogen Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Strongbridge Biopharma plc 176.65% 0% -60.6%
Achaogen Inc. -2,046.32% -227.2% -113.1%

Risk and Volatility

Strongbridge Biopharma plc’s current beta is 0.22 and it happens to be 78.00% less volatile than Standard and Poor’s 500. Achaogen Inc. has a 0.84 beta and it is 16.00% less volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Strongbridge Biopharma plc are 3.4 and 3.1 respectively. Its competitor Achaogen Inc.’s Current Ratio is 2.5 and its Quick Ratio is 2.5. Strongbridge Biopharma plc can pay off short and long-term obligations better than Achaogen Inc.

Analyst Recommendations

Strongbridge Biopharma plc and Achaogen Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Strongbridge Biopharma plc 0 0 0 0.00
Achaogen Inc. 0 6 0 2.00

Meanwhile, Achaogen Inc.’s consensus target price is $2.75, while its potential upside is 388.19%.

Insider and Institutional Ownership

Roughly 75.1% of Strongbridge Biopharma plc shares are owned by institutional investors while 36.2% of Achaogen Inc. are owned by institutional investors. Insiders owned 10.17% of Strongbridge Biopharma plc shares. Competitively, insiders own roughly 16.9% of Achaogen Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Strongbridge Biopharma plc 6.88% 12.58% 2.72% -7.37% -28.16% 17.86%
Achaogen Inc. -5.41% -49.38% -57.77% -85.3% -92.67% -37.85%

For the past year Strongbridge Biopharma plc has 17.86% stronger performance while Achaogen Inc. has -37.85% weaker performance.

Summary

On 10 of the 11 factors Strongbridge Biopharma plc beats Achaogen Inc.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States, Sweden, and Cayman Islands. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. It is also involved in developing Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical development for the treatment of endogenous CushingÂ’s syndrome; and Veldoreotide, a novel somatostatin analogue that is in Phase II clinical development to treat acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to to enable patients to receive safe and efficacious doses of plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California.